Compile Data Set for Download or QSAR
Report error Found 366 Enz. Inhib. hit(s) with all data for entry = 11750
TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644447(US11866436, Example 41 | 5-((2-(4-((3-cyano-4- cyc...)
Affinity DataIC50: 0.145nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644585((R)-5-((1-(4-((3-fluoro-4-(trifluoromethoxy)benzyl...)
Affinity DataIC50: 0.180nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644445(US11866436, Example 39 | 5-((2-(4-((3-cyano-4- cyc...)
Affinity DataIC50: 0.197nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644580(5-((2-(4-((3-((1H-pyrazol-4-yl)methyl)-5-(trifluor...)
Affinity DataIC50: 0.201nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644448(US11866436, Example 42 | 5-((2-(4-((3-chloro- 5-(c...)
Affinity DataIC50: 0.203nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644564(5-((2-(4-((3- (oxazol-5- ylmethyl)-5- (trifluorome...)
Affinity DataIC50: 0.217nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644439(US11866436, Example 33 | 5-((2-(4-((3-Chloro-4-cyc...)
Affinity DataIC50: 0.221nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644578(5-((2-(4-((3- (furan-3- ylmethyl)-5- (trifluoromet...)
Affinity DataIC50: 0.223nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644583(5-((2-(4- ((3,5- difluoro-4- (trifluoro- methoxy) ...)
Affinity DataIC50: 0.236nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644417(US11866436, Example 11 | 5-((2-(4-((3-chloro-4- (c...)
Affinity DataIC50: 0.244nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644440(US11866436, Example 34 | 5-((2-(4-((3-chloro-4- cy...)
Affinity DataIC50: 0.248nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644520(US11866436, Example 115 | 5-(2-(4-((3- bromo-5- (t...)
Affinity DataIC50: 0.248nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644506(US11866436, Example 101 | 5-(3-(4-((3- fluoro-4- (...)
Affinity DataIC50: 0.258nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644511(US11866436, Example 106 | 5-((2-(4-((3- chloro-5- ...)
Affinity DataIC50: 0.263nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644577(5-((2-(4-((3- ((1H-imidazol- 1-yl)methyl)-5- (trif...)
Affinity DataIC50: 0.265nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644426(US11866436, Example 20 | 5-((2-(4-((3- cyano-4- cy...)
Affinity DataIC50: 0.278nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644409(US11866436, Example 3 | 5-((2-(4-((3-chloro- 4-(tr...)
Affinity DataIC50: 0.298nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644513(US11866436, Example 108 | 5-((2-(4-((3- (cyanometh...)
Affinity DataIC50: 0.304nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644408(US11866436, Example 2 | 5-((2-(4-(((2-Chloro-[1,1&...)
Affinity DataIC50: 0.306nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644521(US11866436, Example 116 | 5-(2-(4-((3,5-difluoro-4...)
Affinity DataIC50: 0.318nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644507(US11866436, Example 102 | 5-(3-(4-((3- chloro-5- (...)
Affinity DataIC50: 0.324nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644534(5-(2-(4-((3- chloro-5-(1- cyano- cyclopropyl) benz...)
Affinity DataIC50: 0.333nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644519(US11866436, Example 114 | 5-(2-(4-((3- chloro-5- (...)
Affinity DataIC50: 0.342nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644434(US11866436, Example 28 | 5-((2-(4-((3- fluoro-4- (...)
Affinity DataIC50: 0.346nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644545(5-((2-(4-((3- (cyanomethyl)- 5-(2,2,2- trifluoroet...)
Affinity DataIC50: 0.349nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644516(US11866436, Example 111 | 5-(2-(4-((3- (cyanomethy...)
Affinity DataIC50: 0.354nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644498(US11866436, Example 93 | 5-(2-(4-((3- fluoro-4- (t...)
Affinity DataIC50: 0.354nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644493(US11866436, Example 88 | (R)-5-((1-(4-((3-chloro-4...)
Affinity DataIC50: 0.359nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644491(US11866436, Example 86 | (S)-5-((1-(4-((3-Chloro-4...)
Affinity DataIC50: 0.361nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644522(US11866436, Example 117 | 5-(2-(4-((3- cyclopropyl...)
Affinity DataIC50: 0.365nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644431(US11866436, Example 25 | 5-((2-(4-((3-Chloro-4-cyc...)
Affinity DataIC50: 0.366nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644537(5-(2-(4-((3- methyl-4- (trifluoro- methoxy) benzyl...)
Affinity DataIC50: 0.370nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644416(US11866436, Example 10 | 5-((2-(4-((3-chloro-4- cy...)
Affinity DataIC50: 0.372nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644412(US11866436, Example 6 | 5-((2-(4-(((2- chloro-2'- ...)
Affinity DataIC50: 0.378nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644421(US11866436, Example 15 | 5-((2-(4-((3-Chloro-4-(tr...)
Affinity DataIC50: 0.382nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644570(5-((2-(4-((3-(2- hydroxyethyl)-5- (trifluoromethox...)
Affinity DataIC50: 0.390nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644446(US11866436, Example 40 | 5-((2-(4-((3-Chloro-5-(cy...)
Affinity DataIC50: 0.403nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644538(5-(2-(4-((3- methoxy-4- (trifluoro- methoxy) benzy...)
Affinity DataIC50: 0.403nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644452(US11866436, Example 46 | 5-(2-(4-((3-Chloro-4-(tri...)
Affinity DataIC50: 0.404nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644518(US11866436, Example 113 | 5-(2-(4-((4- chloro-3- (...)
Affinity DataIC50: 0.409nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644517(US11866436, Example 112 | 5-(2-(4-((3- bromo-4- (t...)
Affinity DataIC50: 0.411nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644500(US11866436, Example 95 | 5-(2-(4-((3- (cyanomethyl...)
Affinity DataIC50: 0.418nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644407(US11866436, Example 1 | 5-((2-(4-((4-cyclobutoxy-3...)
Affinity DataIC50: 0.425nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644462(US11866436, Example 56 | 5-((2-(4-((3- (cyanomethy...)
Affinity DataIC50: 0.427nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644586((R)-5-((1-(4-((3-fluoro-4-(trifluoromethoxy)benzyl...)
Affinity DataIC50: 0.428nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644536(5-(2-(4-((3- cyclopropyl-4- (trifluoro- methoxy) b...)
Affinity DataIC50: 0.432nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644443(US11866436, Example 37 | 5-((2-(4-((3- (hydroxymet...)
Affinity DataIC50: 0.436nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644512(US11866436, Example 107 | 5-(2-(4-((3- (cyanomethy...)
Affinity DataIC50: 0.437nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644508(US11866436, Example 103 | 5-(3-(4-((3- (cyanomethy...)
Affinity DataIC50: 0.453nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644547(5-(3-(4-((3- cyclopropyl-4- (trifluoro- methoxy) b...)
Affinity DataIC50: 0.457nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

Displayed 1 to 50 (of 366 total ) | Next | Last >>
Jump to: